nitroglycerin has been researched along with No-Reflow Phenomenon in 8 studies
Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.
nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.
nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.
No-Reflow Phenomenon: Markedly reduced or absent REPERFUSION in an infarct zone following the removal of an obstruction or constriction of an artery.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alprostadil is a kind of liposomal prostaglandin E1 with beneficial effects on vasodilation, platelet disaggregation and fibrinolysis." | 2.87 | Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon. ( Ding, S; Ge, H; He, B; He, J; Kong, L; Pu, J; Sheng, X; Sun, Y, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, X | 1 |
| Zhou, J | 1 |
| Zhang, Y | 1 |
| Li, Q | 1 |
| Guo, L | 1 |
| Mao, Y | 1 |
| He, L | 1 |
| Sheng, X | 1 |
| Ding, S | 1 |
| Ge, H | 1 |
| Sun, Y | 1 |
| Kong, L | 1 |
| He, J | 1 |
| Pu, J | 1 |
| He, B | 1 |
| Sani, HD | 1 |
| Eshraghi, A | 1 |
| Nezafati, MH | 1 |
| Vojdanparast, M | 1 |
| Shahri, B | 1 |
| Nezafati, P | 1 |
| Park, CB | 1 |
| Cho, JM | 1 |
| Kim, DH | 1 |
| Kim, CJ | 1 |
| Chang, SF | 1 |
| Ma, JY | 1 |
| Qian, JY | 1 |
| Shu, XH | 1 |
| Ge, JB | 1 |
| Wilson, W | 1 |
| Eccleston, D | 1 |
| Kopetz, V | 1 |
| Kennedy, J | 1 |
| Heresztyn, T | 1 |
| Stafford, I | 1 |
| Willoughby, SR | 1 |
| Beltrame, JF | 1 |
| Ozdogru, I | 1 |
| Zencir, C | 1 |
| Dogan, A | 1 |
| Orscelik, O | 1 |
| Inanc, MT | 1 |
| Celik, A | 1 |
| Gur, M | 1 |
| Elbasan, Z | 1 |
| Kalay, N | 1 |
| Oguzhan, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| EARLY Microvascular Dysfunction Prediction Using Quantitative Flow Ratio in ST-segment Elevation MYOcardial Infarction Patients With Pharmaco-Invasive Strategy (EARLY-MYO-QFR PI)[NCT04220736] | 200 participants (Anticipated) | Observational | 2018-01-01 | Recruiting | |||
| EARLY Microvascular Dysfunction Prediction Using Quantitative Flow Ratio After ST-segment Elevation MYOcardial Infarction (EARLY-MYO-QFR I)[NCT03780335] | 162 participants (Actual) | Observational | 2015-01-01 | Completed | |||
| EARLY Microvascular Dysfunction Assessment Using Quantitative Flow Ratio After ST-segment Elevation MYOcardial Infarction (EARLY-MYO-QFR II)[NCT03910400] | 200 participants (Anticipated) | Interventional | 2019-02-01 | Recruiting | |||
| Intracoronary Infusion of Alprostadil and Nitroglycerin With Targeted Perfusion Microcatheter in STEMI Patients With Coronary Slow Flow Phenomenon[NCT03296670] | Phase 4 | 57 participants (Actual) | Interventional | 2015-08-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for nitroglycerin and No-Reflow Phenomenon
| Article | Year |
|---|---|
Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.
Topics: Aged; Alprostadil; Catheters; Double-Blind Method; Drug Delivery Systems; Female; Humans; Infusions, | 2018 |
Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.
Topics: Aged; Alprostadil; Catheters; Double-Blind Method; Drug Delivery Systems; Female; Humans; Infusions, | 2018 |
Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.
Topics: Aged; Alprostadil; Catheters; Double-Blind Method; Drug Delivery Systems; Female; Humans; Infusions, | 2018 |
Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.
Topics: Aged; Alprostadil; Catheters; Double-Blind Method; Drug Delivery Systems; Female; Humans; Infusions, | 2018 |
Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.
Topics: Aged; Alprostadil; Catheters; Double-Blind Method; Drug Delivery Systems; Female; Humans; Infusions, | 2018 |
Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.
Topics: Aged; Alprostadil; Catheters; Double-Blind Method; Drug Delivery Systems; Female; Humans; Infusions, | 2018 |
Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.
Topics: Aged; Alprostadil; Catheters; Double-Blind Method; Drug Delivery Systems; Female; Humans; Infusions, | 2018 |
Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.
Topics: Aged; Alprostadil; Catheters; Double-Blind Method; Drug Delivery Systems; Female; Humans; Infusions, | 2018 |
Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.
Topics: Aged; Alprostadil; Catheters; Double-Blind Method; Drug Delivery Systems; Female; Humans; Infusions, | 2018 |
Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.
Topics: Aged; Alprostadil; Catheters; Double-Blind Method; Drug Delivery Systems; Female; Humans; Infusions, | 2018 |
Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.
Topics: Aged; Alprostadil; Catheters; Double-Blind Method; Drug Delivery Systems; Female; Humans; Infusions, | 2018 |
Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.
Topics: Aged; Alprostadil; Catheters; Double-Blind Method; Drug Delivery Systems; Female; Humans; Infusions, | 2018 |
Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.
Topics: Aged; Alprostadil; Catheters; Double-Blind Method; Drug Delivery Systems; Female; Humans; Infusions, | 2018 |
Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.
Topics: Aged; Alprostadil; Catheters; Double-Blind Method; Drug Delivery Systems; Female; Humans; Infusions, | 2018 |
Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.
Topics: Aged; Alprostadil; Catheters; Double-Blind Method; Drug Delivery Systems; Female; Humans; Infusions, | 2018 |
Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.
Topics: Aged; Alprostadil; Catheters; Double-Blind Method; Drug Delivery Systems; Female; Humans; Infusions, | 2018 |
Nicorandil Versus Nitroglycerin for Symptomatic Relief of Angina in Patients With Slow Coronary Flow Phenomenon: A Randomized Clinical Trial.
Topics: Adult; Aged; Angina Pectoris; Canada; Coronary Angiography; Delayed-Action Preparations; Female; Hum | 2015 |
[Effects of intracoronary administration of nitroglycerin and verapamil for treatment of coronary slow flow phenomenon].
Topics: Adult; Aged; Coronary Circulation; Female; Humans; Male; Middle Aged; Nitroglycerin; No-Reflow Pheno | 2010 |
Endothelial function, oxidative stress and inflammatory studies in chronic coronary slow flow phenomenon patients.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Albuterol; Biomarkers; Coronary Disease; Endothelium, Vas | 2012 |
Acute effects of intracoronary nitroglycerin and diltiazem in coronary slow flow phenomenon.
Topics: Adult; Aged; Coronary Vessels; Diltiazem; Female; Humans; Injections, Intra-Arterial; Male; Middle A | 2013 |
3 other studies available for nitroglycerin and No-Reflow Phenomenon
| Article | Year |
|---|---|
Evaluate the Correlation between the TIMI Frame Count, IMR, and CFR in Coronary Microvascular Disease.
Topics: Coronary Angiography; Coronary Circulation; Coronary Vessels; Humans; Microcirculation; Nitroglyceri | 2022 |
Intracoronary nitroglycerin injection through a microcatheter for coronary no-reflow following percutaneous coronary intervention.
Topics: Humans; Injections; Male; Middle Aged; Nitroglycerin; No-Reflow Phenomenon; Percutaneous Coronary In | 2016 |
How to manage no reflow phenomenon with local drug delivery via a rapid exchange catheter.
Topics: Aged; Angioplasty, Balloon, Coronary; Catheters; Coronary Angiography; Drug Administration Routes; D | 2011 |